Verity A Saunders

Verity A Saunders

UNVERIFIED PROFILE

Are you Verity A Saunders?   Register this Author

Register author
Verity A Saunders

Verity A Saunders

Publications by authors named "Verity A Saunders"

Are you Verity A Saunders?   Register this Author

14Publications

264Reads

19Profile Views

The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression .

Oncotarget 2018 Mar 3;9(17):13423-13437. Epub 2018 Feb 3.

Cancer Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, South Australia.

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/24393
Publisher Site
http://dx.doi.org/10.18632/oncotarget.24393DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862588PMC
March 2018

A Method for Next-Generation Sequencing of Paired Diagnostic and Remission Samples to Detect Mitochondrial DNA Mutations Associated with Leukemia.

J Mol Diagn 2017 09 18;19(5):711-721. Epub 2017 Jul 18.

Cancer Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia; School of Medicine, Faculty of Health Sciences, University of Adelaide, Adelaide, South Australia, Australia; Australasian Leukaemia and Lymphoma Group, Melbourne, Victoria, Australia; Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, South Australia, Australia; Department of Molecular Medicine and Pathology, Flinders University and Medical Centre, Adelaide, South Australia, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmoldx.2017.05.009DOI Listing
September 2017

Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2.

Leuk Lymphoma 2013 Mar 21;54(3):569-78. Epub 2012 Aug 21.

Division of Hematology, SA Pathology, Adelaide, South Australia, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2012.715345DOI Listing
March 2013

Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib.

J Clin Oncol 2010 Jun 26;28(16):2761-7. Epub 2010 Apr 26.

Haematology Department, Centre for Cancer Biology, SA Pathology (IMVS Campus), University of Adelaide, Frome Road, Adelaide, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.26.5819DOI Listing
June 2010